Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malaria chemoprevention after hospital discharge for children with severe acute malnutrition
PACTR202609867402096Phase 3Not yet recruiting
- Sponsor
- Training and Research Unit of Excellence
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in malaria comparing Dihydroartemisinin-piperaquine with Placebo (2 arms). Primary endpoint: All-cause deaths or all-cause re-admissions. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202609867402096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609867402096.